NCT00306878View on ClinicalTrials.gov

Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 31, 1995

Primary Completion Date

May 31, 1997

Study Completion Date

May 31, 1997

Conditions
Psoriasis Vulgaris
Interventions
DRUG

Abatacept

Trial Locations (5)

Unknown

Local Institution, Boston

Local Institution, Ann Arbor

Local Institution, New York

Local Institution, Philadelphia

Local Institution, Pittsburgh

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00306878 - Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris | Biotech Hunter | Biotech Hunter